Oculis Highlights Pipeline Progress Amidst DME Treatment Gap

Event summary

  • Oculis is presenting data at the ARVO 2026 Annual Meeting and Eyecelerator, focusing on its late-stage pipeline for ophthalmic and neuro-ophthalmic diseases.
  • The DME AWARE Delphi Study, sponsored by Oculis, revealed a consensus need for non-invasive treatments for diabetic macular edema (DME).
  • Post-hoc analysis of the ACUITY trial suggests Privosegtor may reduce retinal ganglion cell loss and improve visual acuity in optic neuritis patients.
  • Oculis anticipates topline results for OCS-01 eye drops (for DME) in June 2026, following completion of the Phase 3 DIAMOND program in April 2026.
  • Privosegtor has received Breakthrough Therapy designation from the FDA and PRIME designation from the EMA for optic neuritis.

The big picture

The DME AWARE study underscores a significant unmet need for less invasive treatments in a market estimated to affect 53 million people by 2040. Oculis’ OCS-01, if successful, could represent a paradigm shift away from invasive procedures like intravitreal injections, potentially capturing a substantial share of the market. The company’s focus on neuro-ophthalmology with Privosegtor also positions it to address a rare but high-value therapeutic area with limited competition.

What we're watching

Clinical Adoption
The acceptance of OCS-01 as a non-invasive DME treatment will depend heavily on the clinical data presented and its perceived efficacy compared to existing therapies, potentially disrupting the intravitreal injection market.
Regulatory Risk
The FDA and EMA’s review of Privosegtor’s Breakthrough Therapy and PRIME designations, respectively, will be critical; any unexpected requests for additional data could significantly delay approval and commercialization.
Pipeline Execution
Oculis’ ability to advance Licaminlimab through its registrational program, PREDICT, will be a key indicator of the company’s overall pipeline management capabilities and its ability to deliver on its ambitious goals.

Related topics

Pharmaceuticals Biotechnology